Are ctDNA monitoring tests being used in clinical practice? Which ctDNA monitoring tests are oncologists currently using, and why? What are their unmet needs and expectations from a new test? Purdie Pascoe is delighted to announce the findings from the first wave of our syndicated ctDNA Cancer Monitoring study have been published.

Tumor agnostic indications present specific challenges that must be addressed to achieve a successful launch and ensure wide access for all patients. To prepare for these complex product and indications launches, it is paramount for commercial teams to gain insights on tumor agnostic testing behaviors, including awareness, adoption, drivers and barriers.

Purdie Pascoe is delighted to announce the findings from the second wave of our syndicated ctDNA Cancer Monitoring study have been published and are available to purchase. If you are interested in purchasing both waves, our consultants would be delighted to discuss a special pricing agreement.